Literature DB >> 1539465

Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine.

D J Briggs1, J R Schwenke.   

Abstract

Sera from individuals across the USA and Peace Corps Volunteers (PCV) were assayed for neutralizing antibody to human diploid cell rabies vaccine (HDCV). A pairwise comparison between intramuscular (i.m.) and intradermal (i.d.) administration, PCV and non-PCV, revealed statistically significant differences between i.m. and i.d. for PCV and non-PCV, and between PCV and non-PCV for i.d. and i.m. administration. Survival analysis and frequency tables employing chi 2 tests determined that the percentage probability of maintaining an adequate titre from 1.5-2.0 years after primary vaccination was 99% in non-PCV i.m., 93% in non-PCV i.d., 88% in PCV i.m., and 64% in PCV i.d.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1539465     DOI： 10.1016/0264-410x(92)90029-j

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  5 in total

1.  Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.

Authors:  Xiaowei Zhang; Zhenggang Zhu; Chuanlin Wang
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

2.  Inactivated Rabies Virus-Vectored Immunocontraceptive Vaccine in a Thermo-Responsive Hydrogel Induces High and Persistent Antibodies against Rabies, but Insufficient Antibodies against Gonadotropin-Releasing Hormone for Contraception.

Authors:  Xianfu Wu; Yong Yang; Chantal Kling; Laurie Seigler; Nadia F Gallardo-Romero; Brock E Martin; Todd G Smith; Victoria A Olson
Journal:  Vaccines (Basel)       Date:  2019-07-25

3.  Evidence of rabies virus exposure among humans in the Peruvian Amazon.

Authors:  Amy T Gilbert; Brett W Petersen; Sergio Recuenco; Michael Niezgoda; Jorge Gómez; V Alberto Laguna-Torres; Charles Rupprecht
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

4.  Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

Authors:  D M C Brinkman; C M Jol-van der Zijde; M M ten Dam; J M Vossen; A D M E Osterhaus; F P Kroon; M J D van Tol
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.542

5.  A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis.

Authors:  Chuan Wang; Pawan Dulal; Xiangyang Zhou; Zhiquan Xiang; Hooman Goharriz; Ashley Banyard; Nicky Green; Livia Brunner; Roland Ventura; Nicolas Collin; Simon J Draper; Adrian V S Hill; Rebecca Ashfield; Anthony R Fooks; Hildegund C Ertl; Alexander D Douglas
Journal:  PLoS Negl Trop Dis       Date:  2018-10-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.